Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

rPPG

Biogen Idec building

Biogen to acquire Reata for approximately $7.3bn

The deal gives Biogen access to a recently launched therapy for Friedreich's ataxia

- PMLiVE

Merck’s Keytruda combination shows promise in late-stage breast cancer study

More than 290,000 people are expected to be diagnosed with breast cancer in the US this year

- PMLiVE

UKHSA data reveals a 45% decline in hepatitis C prevalence in England

More than 80,000 people have been treated for the virus by NHS England since 2015

- PMLiVE

UK experts and politicians meet to discuss challenges faced by progressive MS patients

Primary-progressive MS accounts for approximately 10-15% of multiple sclerosis cases

- PMLiVE

AstraZeneca’s rare disease unit to acquire Pfizer’s early-stage gene therapies for $1bn

The transaction could potentially see staff associated with the portfolio move to Alexion

- PMLiVE

Merck’s investigational pneumococcal vaccine shows promise in older adults

V116 is designed to address the strains that represent adult pneumococcal disease

How to Increase Engagement During Virtual Events

Tip #4 - How do you plan the agenda for your virtual event?We suggest to invite participant input to build and personalize the engagement.Invite participant input and rethink your agenda...

Impetus Digital

- PMLiVE

Health and Social Care Committee report on vaccination calls for urgent action in the UK

In England, coverage for childhood immunisations was below target in 2021 and 2022

- PMLiVE

World Health Organization publishes updated essential medicines list

Three medicines that can delay or slow MS disease progression have been included in the EML

- PMLiVE

New research highlights mental health support gap for autoimmune disease patients

More than 1,800 patients with SARDs were surveyed for neurological and psychiatric symptoms

- PMLiVE

Gilead expands IT partnership with Cognizant in deal worth approximately $800m

It is hoped that the collaboration will enable Gilead to bring its medicines to market faster

- PMLiVE

Moderna and Merck’s skin cancer vaccine enters late-stage development

More than 1,000 patients with resected high-risk melanoma will be enrolled in the trial

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links